Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria

NCT00296374 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00296374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00296374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
March 31, 2009
Enrollment
353 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus